ArticleFrontiers in molecular biosciences2025
Integrative proteomics reveals mitochondrial and immune signatures of MLH1 exon 13 deletion in Lynch syndrome-associated colorectal cancer.
Article in Frontiers in molecular biosciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Lynch syndrome is an inherited cancer predisposition caused by pathogenic variants in mismatch repair (MMR) genes. Large genomic rearrangements (LGRs) in MLH1 are often underestimated due to detection challenges. Functional analyses of specific variants such as MLH1 exon 13 deletion (MLH1-EX13 Del) remain scarce. Methods: A three-generation Chinese family with Lynch syndrome was investigated. Targeted next-generation sequencing identified MLH1-EX13 Del in the proband, which was validated by qPCR in family members. Cancer patients underwent MMR immunohistochemistry (IHC) and microsatellite instability (MSI) testing. Data-independent acquisition proteomics was performed on four paired tumor and adjacent tissues, followed by Gene Ontology and KEGG enrichment analyses. Results: Six malignant tumors were diagnosed in the family. All tested carriers harbored MLH1-EX13 Del. IHC showed loss of MLH1 and PMS2, occasionally with focal MLH1 positivity or concurrent MSH2 loss. All tumors tested were MSI-H. Proteomics revealed systemic downregulation of oxidative phosphorylation across mitochondrial respiratory complexes, whereas ribosome biogenesis proteins were upregulated, indicating enhanced protein synthesis. Immune pathway analysis revealed activation of neutrophil-mediated immunity and upregulation of inflammatory markers (S100A8/A9, MPO, ELANE), consistent with an inflamed tumor phenotype. Conclusion: This study provides the first proteomic evidence linking MLH1-EX13 Del to suppressed mitochondrial metabolism and immune activation. These findings highlight metabolic vulnerability and an inflammatory microenvironment as potential therapeutic targets, offering new insights into Lynch syndrome-associated colorectal cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.